Actively Recruiting
In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma
Led by Heather Wachtel · Updated on 2026-02-27
30
Participants Needed
1
Research Sites
182 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study will enroll up to 30 evaluable patients with pheochromocytoma or paraganglioma who are undergoing surgical or systemic treatment. A pre-treatment 18F-FluorThanatrace (\[18F\]FTT) positron emission tomography/computed tomography (PET/CT) scan will be done prior to surgery or systemic therapy. PET/CT imaging will be used to evaluate PARP-1 expression in sites of pheochromocytoma or paraganglioma using the investigational radiotracer \[18F\]FTT. This is an observational study in that \[18F\]FTT PET/CT will not be used to direct treatment decisions. While patients and referring physicians will not be blinded to the \[18F\]FTT PET/CT results, treatment decisions will be made by the treating physicians based upon clinical criteria.
CONDITIONS
Official Title
In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants will be 18 years of age or older.
- Clinical diagnosis of pheochromocytoma or paraganglioma based on biochemical and imaging studies.
- At least one lesion identified on standard imaging such as CT, MRI, FDG or 68-Gallium dotatate PET/CT, or MIBG.
- Germline genetic testing performed for clinical purposes or consent provided for research genetic testing.
- Willing to provide written informed consent and participate according to guidelines.
You will not qualify if you...
- Unable to tolerate imaging procedures as determined by investigator or treating physician.
- Pregnant or breastfeeding females; urine pregnancy test required for women of child-bearing potential.
- Any current medical condition or disorder that could compromise safety or participation as assessed by physician.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
Research Team
H
Heather Wachtel, MD
CONTACT
J
Julia T Lewandowski
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here